{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:23:34Z","timestamp":1772166214532,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,16]],"date-time":"2021-02-16T00:00:00Z","timestamp":1613433600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prompt diagnosis of juvenile idiopathic arthritis (JIA) is important to avoid long term complications. Elevated serum 14\u20133-3\u03b7 levels improve the diagnostic sensitivity of rheumatoid factor (RF) and cyclic citrullinated peptide (CCP) antibody in adult rheumatoid arthritis (RA), and have been associated with more severe phenotype. We investigated the prevalence and clinical significance of serum 14\u20133-3\u03b7 in different types of JIA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      JIA patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009151) followed by the Pediatric Rheumatology Core at Children\u2019s Hospital of Los Angeles were categorized into 5 groups: polyarticular JIA RF+ (PJIA RF+;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200939), PJIA RF- (n\u2009=\u200939), psoriatic arthritis (PsA;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200919), enthesitis-related arthritis (ERA;\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200918), and oligoarticular JIA (OJIA [control group];\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200936). RF, CCP antibody, and 14\u20133-3\u03b7 were measured for all patients. 14\u20133-3\u03b7 serum levels\n                      <jats:underline>&gt;<\/jats:underline>\n                      \u20090.2\u2009ng\/mL were considered positive. Disease activity was assessed by the Juvenile Arthritis Disease Activity Score-71 (JADAS-71).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Elevated 14\u20133-3\u03b7 levels were detected in 34\/151 (23%) patients, and across all groups tested. Most patients with 14\u20133-3\u03b7 had titers \u22654 times above the cutoff value. The majority (22, 65%) of 14\u20133-3\u03b7-positive patients were also positive for RF or CCP antibodies, 16 (47%) were positive for all 3, and 12 (35%) were single-positive for 14\u20133-3\u03b7. The highest prevalence of 14\u20133-3\u03b7 was in PJIA RF+ patients (49%), followed by OJIA (22%). Positivity for 14\u20133-3\u03b7 was not significantly associated with disease activity or age at diagnosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Serum 14\u20133-3\u03b7 can be detected in all forms of JIA tested but appears to be most common in PJIA RF+. 14\u20133-3\u03b7 does not appear to correlate with disease activity in JIA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12969-021-00502-8","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T12:17:14Z","timestamp":1613564234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prevalence and significance of serum 14\u20133-3\u03b7 in juvenile idiopathic arthritis"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7917-0402","authenticated-orcid":false,"given":"Iris","family":"Reyhan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga S.","family":"Zhukov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Lagier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert F.","family":"Bridgforth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary J.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna M.","family":"Popov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanley J.","family":"Naides","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Reiff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,16]]},"reference":[{"issue":"4","key":"502_CR1","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/acr.20460","volume":"63","author":"T Beukelman","year":"2011","unstructured":"Beukelman T, Patkar NM, Saag KG, Tolleson-Rinehart S, Cron RQ, DeWitt EM, et al. 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken). 2011;63(4):465\u201382. https:\/\/doi.org\/10.1002\/acr.20460.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"502_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1546-0096-11-31","volume":"11","author":"BE Gillima","year":"2013","unstructured":"Gillima BE, Chauhan AK, Moore TL. Evaluation of anti-citrullinated type II collagen and anti-citrullinated vimentin antibodies in patients with juvenile idiopathic arthritis. Pediatr Rheumatol. 2013;11:13. https:\/\/doi.org\/10.1186\/1546-0096-11-31.","journal-title":"Pediatr Rheumatol"},{"issue":"9","key":"502_CR3","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.19082\/2897","volume":"8","author":"M Hamooda","year":"2016","unstructured":"Hamooda M, Fouad H, Nermeen G, Sewelam N, Magahed D. Anti-cyclic citrullinated peptide antibodies in children with juvenile idiopathic arthritis. Electron Physician. 2016;8(9):2891\u2013903. https:\/\/doi.org\/10.19082\/2897.","journal-title":"Electron Physician"},{"issue":"12","key":"502_CR4","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1515\/CCLM.2009.288","volume":"47","author":"AT Kuna","year":"2009","unstructured":"Kuna AT, Lamot L, Miler M, Harjacek M, Simundic AM, Vrkic N. Antibodies to mutated citrullinated vimentin and antibodies to cyclic citrullinated peptides in juvenile idiopathic arthritis. Clin Chem Lab Med. 2009;47(12):1525\u201330. https:\/\/doi.org\/10.1515\/CCLM.2009.288.","journal-title":"Clin Chem Lab Med"},{"key":"502_CR5","doi-asserted-by":"publisher","first-page":"379","DOI":"10.2147\/CLEP.S53168","volume":"6","author":"EJ Oberle","year":"2014","unstructured":"Oberle EJ, Harris JG, Verbsky JW. Polyarticular juvenile idiopathic arthritis \u2013 epidemiology and management approaches. Clin Epidemiol. 2014;6:379\u201393. https:\/\/doi.org\/10.2147\/CLEP.S53168.","journal-title":"Clin Epidemiol"},{"issue":"8","key":"502_CR6","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/rheumatology\/kep144","volume":"48","author":"S Ringold","year":"2009","unstructured":"Ringold S, Seidel KD, Koepsell TD, Wallace CA. Inactive disease in polyarticular juvenile idiopathic arthritis: current patterns and associations. Rheumatology (Oxford). 2009;48(8):972\u20137. https:\/\/doi.org\/10.1093\/rheumatology\/kep144.","journal-title":"Rheumatology (Oxford)"},{"key":"502_CR7","doi-asserted-by":"publisher","first-page":"715","DOI":"10.3899\/jrheum.120602","volume":"40","author":"L Bertilsson","year":"2013","unstructured":"Bertilsson L, Andersson-Gare B, Fasth A, Petersson IF, Forsblad-D\u2019elia H. Disease course, outcome, and predictors of outcome in population-based juvenile chronic arthritis cohort followed by 17 years. J Rheumatol. 2013;40:715\u201324. https:\/\/doi.org\/10.3899\/jrheum.120602.","journal-title":"J Rheumatol"},{"issue":"suppl","key":"502_CR8","first-page":"S-35-9","volume":"32","author":"WP Maksymowych","year":"2014","unstructured":"Maksymowych WP, Marotta A. 14\u20133-3\u03b7: a novel biomarker platform for rheumatoid arthritis. Clin Exp Rheumatol. 2014;32(suppl):S-35-9.","journal-title":"Clin Exp Rheumatol"},{"key":"502_CR9","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.3899\/jrheum.131446","volume":"41","author":"WP Maksymowych","year":"2014","unstructured":"Maksymowych WP, Naides SJ, Bykerk V, Siminovitch KA, van Schaardenburg D, Boers, et al. Serum 14-3-3\u03b7 is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. J Rheumatol. 2014;41:2104\u201313. https:\/\/doi.org\/10.3899\/jrheum.131446.","journal-title":"J Rheumatol"},{"key":"502_CR10","doi-asserted-by":"publisher","first-page":"R99","DOI":"10.1186\/ar4547","volume":"16","author":"WP Maksmowych","year":"2014","unstructured":"Maksmowych WP, van der Heijde D, Allaart CF, Landewe R, Boire G, Tak PP, et al. 14-3-3\u03b7 is a novel mediator associated with pathogenesis of rheumatoid arthritis and joint damage. Arthritis Res Ther. 2014;16:R99. https:\/\/doi.org\/10.1186\/ar4547.","journal-title":"Arthritis Res Ther"},{"key":"502_CR11","first-page":"S587","volume":"65","author":"D van Schaardenburg","year":"2013","unstructured":"van Schaardenburg D, Dhaliwal R, Maksymowych WP, Marotta A, van Breemen J. Serum 14\u20133-3 precedes and independently predicts the development of RA [abstract]. Arth Rheum. 2013;65:S587 https:\/\/acrabstracts.org\/abstract\/serum-14-3-3%ce%b7-precedes-andindependently-predicts-the-development-of-ra\/.","journal-title":"Arth Rheum"},{"issue":"Supplement","key":"502_CR12","first-page":"L13","volume":"65","author":"D van Schaardenburg","year":"2013","unstructured":"van Schaardenburg D, van Beers-Tas M, Britsemmer K, Murphy M, Maksymowych WP, Boers M, et al. Serum 14\u20133-3\u03b7 Marks RA Development in Arthralgia and Radiographic Progression in Early RA Patients [abstract]. Arth Rheum. 2013;65(Supplement):L13 https:\/\/acrabstracts.org\/abstract\/serum-14-3-3%ce%b7-marks-radevelopment-in-arthralgia-and-radiographic-progression-in-early-ra-patients\/.","journal-title":"Arth Rheum"},{"key":"502_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s13075-016-0975-4","volume":"18","author":"MH van Beers-Tas","year":"2016","unstructured":"van Beers-Tas MH, Marotta A, Boers M, Maksymowych WP, van Schaardenburg D. A prospective cohort study of 14-3-3\u03b7 in ACPA and\/or RF-positive patients with arthralgia. Arthritis Res Ther. 2016;18:76. https:\/\/doi.org\/10.1186\/s13075-016-0975-4.","journal-title":"Arthritis Res Ther"},{"key":"502_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13075-016-0935-z","volume":"18","author":"N Carrier","year":"2016","unstructured":"Carrier N, Marotta A, de Brum-Fernandes AJ, Liang P, Masetto A, Menard HA, Maksymowych WP, et al. Serum levels of 14-3-3\u03b7 protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritis. Arthritis Res Ther. 2016;18:37. https:\/\/doi.org\/10.1186\/s13075-016-0935-z.","journal-title":"Arthritis Res Ther"},{"key":"502_CR15","unstructured":"Feller L, Dalrymple AM, Tuttle P IV, Syed RH, Pepmueller P, Moore T. Examination of the Clinical Significance of 14-3-3 Eta in Juvenile Idiopathic\u00a0Arthritis [abstract]. Arthritis Rheumatol. 2015;67(suppl 10). https:\/\/acrabstracts.org\/abstract\/examination-of-the-clinical-significance-of-14-3-3-eta-in-juvenile-idiopathic-arthritis\/. Accessed 10 Feb 2021."},{"key":"502_CR16","unstructured":"Dalrymple AM, Tuttle P IV, Feller L, Zhukov OS, Lagier RJ, Bridgforth R, Williams GJ, Popov JM, Naides SJ, Moore T. 14-3-3\u03b7 (eta) Protein in Juvenile\u00a0Idiopathic Arthritis (JIA) Patients [abstract]. Arthritis Rheumatol. 2017;69(suppl 10). https:\/\/acrabstracts.org\/abstract\/14-3-3%ce%b7-eta-protein-in-juvenile-idiopathic-arthritis-jia-patients\/. Accessed 10 Feb 2021."},{"key":"502_CR17","doi-asserted-by":"crossref","unstructured":"Rosenberg AM, Maksymowych W, Gui Y, Marotta A. Serum 14-3-3\u03b7 Is Present in JIA and Is Not Associated with RF+ Polyarthritis [abstract]. Arthritis\u00a0Rheumatol. 2015;67(suppl 10). https:\/\/acrabstracts.org\/abstract\/serum-14-3-3-is-present-in-jia-and-is-not-associated-with-rf-polyarthritis\/. Accessed 10 Feb 2021.","DOI":"10.1136\/annrheumdis-2015-eular.2369"},{"key":"502_CR18","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/art.24516","volume":"61","author":"A Consolaro","year":"2009","unstructured":"Consolaro A, Ruperto N, Bazso A, Pistorio A, Magni-Manzoni S, Filocamo G, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum. 2009;61:658\u201366. https:\/\/doi.org\/10.1002\/art.24516.","journal-title":"Arthritis Rheum"},{"key":"502_CR19","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1002\/art.1780371209","volume":"37","author":"G Singh","year":"1994","unstructured":"Singh G, Athreya BH, Fries JF, Oldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum. 1994;37:1761. https:\/\/doi.org\/10.1002\/art.1780371209.","journal-title":"Arthritis Rheum"},{"key":"502_CR20","unstructured":"Core Team R. R: a language and environment for statistical computing. In: R Foundation for statistical computing. Vienna, Austria; 2020. https:\/\/www.R-project.org\/."},{"issue":"4","key":"502_CR21","doi-asserted-by":"publisher","first-page":"799","DOI":"10.3899\/jrheum.150891","volume":"43","author":"L Fitzpatrick","year":"2016","unstructured":"Fitzpatrick L, Broadaway KA, Ponder L, Angeles-Hans ST, Jenkins K, Rouster-Stevens K, et al. Phenotypic characterization of juvenile idiopathic arthritis in African American children. J Rheumatol. 2016;43(4):799\u2013803. https:\/\/doi.org\/10.3899\/jrheum.150891.","journal-title":"J Rheumatol"},{"issue":"9","key":"502_CR22","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.3899\/jrheum.141385","volume":"42","author":"WP Maksymowych","year":"2015","unstructured":"Maksymowych WP, Boire G, van Schaardenburg D, Wichuk S, Turk S, Boers M, et al. 14-3-3\u03b7 autoantibodies: diagnostic use in early rheumatoid arthritis. J Rheumatol. 2015;42(9):1587\u201394. https:\/\/doi.org\/10.3899\/jrheum.141385.","journal-title":"J Rheumatol"},{"key":"502_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3899\/jrheum.150330","volume":"42","author":"SJ Naides","year":"2015","unstructured":"Naides SJ, Marotta A. 14-3-3\u03b7 in Seronegative rheumatoid arthritis. J Rheumatol. 2015;42:10. https:\/\/doi.org\/10.3899\/jrheum.150330.","journal-title":"J Rheumatol"},{"issue":"1","key":"502_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s12098-010-0006-4","volume":"77","author":"R Gupta","year":"2010","unstructured":"Gupta R, Thabah MM, Vaidya B, Gupta S, Lodha R, Kabra SK. Anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Indian J Pediatr. 2010;77(1):41\u20134. https:\/\/doi.org\/10.1007\/s12098-010-0006-4.","journal-title":"Indian J Pediatr"},{"issue":"1","key":"502_CR25","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jbspin.2012.03.008","volume":"80","author":"A Omar","year":"2013","unstructured":"Omar A, Abo-Elyoun I, Hussein H, Nabih M, Atwa H, Gad S. Anti-cyclic citrullinated peptide (anti-CCP) antibody in juvenile idiopathic arthritis (JIA): correlations with disease activity and severity of joint damage (a multicenter trial). Joint bone Spine. 2013;80(1):38\u201343. https:\/\/doi.org\/10.1016\/j.jbspin.2012.03.008.","journal-title":"Joint bone Spine"},{"issue":"8","key":"502_CR26","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1080\/08820130802438057","volume":"37","author":"HM Habib","year":"2008","unstructured":"Habib HM, Mosaad YM, Youssef HM. Anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Immunol Investig. 2008;37(8):849\u201357. https:\/\/doi.org\/10.1080\/08820130802438057.","journal-title":"Immunol Investig"},{"issue":"9","key":"502_CR27","first-page":"1829","volume":"31","author":"JM Low","year":"2004","unstructured":"Low JM, Chauhan AK, Kietz DA, Daud U, Permueller PH, Moore TL. Determination of anti-cyclic Citrullinated peptide antibodies in the sera of patients with juvenile idiopathic arthritis. J Rheumatol. 2004;31(9):1829\u201333.","journal-title":"J Rheumatol"},{"issue":"1","key":"502_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1546-0096-10-29","volume":"10","author":"AE Tebo","year":"2012","unstructured":"Tebo AE, Jaskowski T, Dais KW, Whiting A, Clifford B, Zeft A, et al. Profiling anti-cyclic citrullinated peptide antibodies in patients with juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2012;10(1):29. https:\/\/doi.org\/10.1186\/1546-0096-10-29.","journal-title":"Pediatr Rheumatol Online J"},{"key":"502_CR29","first-page":"S247","volume":"64","author":"A Marotta","year":"2012","unstructured":"Marotta A, van Kuijk AW, Maksymowych WP. Tak PP. 14\u20133-3 Eta is a modifiable serum biomarker that marks adalimumab response in psoriatic arthritis [abstract]. Arthritis Rheum. 2012;64:S247 https:\/\/acrabstracts.org\/abstract\/14-3-3-eta-is-a-modiable-serumbiomarker-that-marks-adalimumab-response-in-psoriatic-arthritis\/.","journal-title":"Arthritis Rheum"},{"key":"502_CR30","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1186\/s13075-015-0799-7","volume":"17","author":"S Hirata","year":"2015","unstructured":"Hirata S, Marotta A, Gui Y, Hanami K, Tanaka Y. Serum 14-3-3\u03b7 level is associated with severity and clinical outcomes of rheumatoid arthritis, and its pretreatment level is predictive of DAS28 remission with tocilizumab. Arthritis Res Ther. 2015;17:280. https:\/\/doi.org\/10.1186\/s13075-015-0799-7.","journal-title":"Arthritis Res Ther"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00502-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12969-021-00502-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00502-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T12:36:34Z","timestamp":1613565394000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-021-00502-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,16]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["502"],"URL":"https:\/\/doi.org\/10.1186\/s12969-021-00502-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-26035\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-26035\/v1","asserted-by":"object"}]},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,16]]},"assertion":[{"value":"6 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol was approved by the Children\u2019s Hospital of Los Angeles institutional review board IRB): CHLA-15-00482.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained from all authors and have reviewed the article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Multiple researchers involved in our study are or were Quest Diagnostics employees and one employee had stock at Quest Diagnostics in the last year.Iris Reyhan MD.Conflict of Interest: None.Olga S. Zhukov, MS MB (ASCP).Conflict of Interest: Quest Diagnostics Employee, stock, stock options.Robert J. Lagier, MS.Conflict of Interest: Quest Diagnostics Employee.Robert F. Bridgforth.Conflict of Interest: former Quest Diagnostics Employee.Gary J. Williams, PhD.Conflict of Interest: former Quest Diagnostics Employee, stocks.Joanna M. Popov, MD PhD.Conflict of Interest: Quest Diagnostics Employee.Stanley J. Naides, MD.Conflict of Interest: formerly Quest Diagnostics Employee, stock, stock options.Andreas Reiff, MD.Conflict of Interest: None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"14"}}